StockGuru Leader Board: NewLink Genetics Corporation (NASDAQ: NLNK) Closed Up 9.12% on Thursday

NewLink Genetics Corporation (NASDAQ: NLNK) is on The StockGuru Leader Board today.  The stock closed up 9.12% on Thursday.

Volume was 18,486 shares traded.

Join in on the Discussion about NLNK

About the Company:

NewLink Genetics Corporation operates as a biopharmaceutical company. It focuses on discovering, developing, and commercializing immunotherapeutic products to enhance cancer treatment options for patients and physicians. Its product portfolio includes biologic and small-molecule immunotherapy product candidates based on proprietary HyperAcute immunotherapy technology for the treatment of various oncology indications. The company primarily develops HyperAcute product candidates, including HyperAcute Pancreas, a Phase III clinical trials product for the treatment of surgically-resected pancreatic cancer patients; HyperAcute Lung, a Phase I/II clinical trials product targeting non-small cell lung cancer; and HyperAcute Melanoma, a Phase II clinical trials product for the treatment of melanoma. It also develops d-1-methyltryptophan or D-1MT, a small-molecule orally bioavailable product candidate that is in Phase IB/II clinical trials for the treatment of metastatic solid tumors. The company has collaboration agreement with National Cancer Institute. NewLink Genetics Corporation was founded in 1999 and is headquartered in Ames, Iowa.

About the StockGuru Leader Board:

We watch for stocks moving up and creating a positive momentum in the market.  We are not compensated for coverage.

Feel free to suggest a stock for coverage if you see it breaking out.  Contact:
IR Affiliates –
StoneBridge Web & SEO –

All content on is original content – with the exception of client news releases. All content is (C) Copyright 2002 to 2012 StockGuru. No content may be used in whole or in part without the express written consent of our Publisher. We encourage web sites interested in our content to offer a reciprocal exchange agreement in exchange for use of some of our content. We do not offer advance approval, but contact our Publisher if you have an interest in repropagating our content. Contact as at: or (469) 252-3030. Mailing address: 1601 Berwick Drive; McKinney, Texas 75070